Recs

6

Tomorrow's Monster Stocks?

Stocks that climb to 10 times their original price are rare breeds -- but they're not impossible to find. Especially when you have Fools for friends.

The market's best stocks include companies that have risen dozens of times in value over the past decade. These aren't penny stocks; they're viable companies with sound business prospects, achieving phenomenal returns every year. Finding just one or two of these monstrously successful firms can help you establish a winning portfolio.

Stalking the monster
To find tomorrow's winners, we'll enlist the more than 130,000 monster trackers at Motley Fool CAPS. We've compiled a list of the most successful CAPS members, dubbed All-Stars, whose picks have doubled, tripled, or even quadrupled in price. Then we've plucked out some of their recent picks for stocks they find equally promising.

Player

CAPS Member Rating

Monster Stock

CAPS Score

Recent Stock Pick

CAPS Rating (out of 5 max)

BravoBevo

99.99

Tortoise Energy Infrastructure

233.57

Gruma (NYSE: GMK  )

*****

Theige

99.54

The9 (Nasdaq: NCTY  )

512.70

Adobe (Nasdaq: ADBE  )

****

BSoutshined

98.20

Ashland (NYSE: ASH  )

158.90

Varian Medical Systems (NYSE: VAR  )

****

tgga99

98.16

CNH Global

106.09

StatoilHydro (NYSE: STO  )

*****

i12Bravo

97.28

Dendreon

518.03

Shengdatech (Nasdaq: SDTH  )

*****

Of course, this is not a list of stocks to buy -- or, for those monster stocks that our CAPS All-Stars have already found, sell. Just consider them starting points for your own further research of extreme buying opportunities.

In search of Bigfoot
The Internet and our living room entertainment centers continue to inch ever closer to each other. Adobe recently announced plans to join forces with entertainment and computing powerhouses to bring its Flash player to televisions. The move should provide more seamless delivery of high-def movies, streaming video, and Flash-based video games. Switching quickly from television programming to online content will further integrate the computer into our lives. (I can't wait for pop-up ads during a movie!)

Such partnerships on Adobe's part may help combat the softness seen in its recent quarterly earnings report. Sales tumbled 13%, even though earnings held the line through a series of sharp cost-cutting maneuvers. While Adobe derives the bulk of its revenue from its Creative Suite software, getting Flash-enabled TVs and set-top boxes onto the market later this year could provide a nice boost to its top line, considering that 80% of all online videos run on the Flash platform.

Microsoft's Silverlight software had some observers convinced that Adobe was running scared, as Mr. Softy's tech powered high-profile broadcasts of the Olympics and NCAA basketball tournaments. Investors doubtlessly wonder whether Adobe's Flash deals will allow it to steal some of Microsoft's growing thunder in online video.

As CAPS member dudemonkey points out, Adobe's competitive moat for Flash is as wide as it is unique:

If you work in the creative industry, you probably use Adobe software. Photoshop is the industry standard application for graphical creation and modification and the open source competition is not as feature-rich as Adobe's offering. Adobe owns Flash, which has long been the best platform for delivering rich web user interfaces to users ... Moats in the tech industry are difficult to come by and don't last long, but Adobe's got one and it's not expensive.

A chance for scary growth
It takes more than a few All-Star picks and a quick paragraph to make buy or sell decisions on a stock. Start your own research on these candidates on Motley Fool CAPS, where you can read a company's financial reports, scrutinize key data and charts, and examine the comments your fellow investors have made, all from a stock's CAPS page. While you're there, weigh in with your own thoughts on whether you think these are tomorrow's monster stocks.

The Steve Jobs Betrayal
You may already know that in the final year of his life, Jobs revealed a stunning betrayal — and told his biographer, "I will spend my last dying breath... and every penny of Apple's $40 billion in the bank to right this wrong." What was it that made Jobs so irate — and why could it make a few in-the-know investors some major profits over the coming months and years?

Enter your email address below to find out what made Jobs so enraged!

StatoilHydro is a Motley Fool Income Investor recommendation. Microsoft is a Motley Fool Inside Value recommendation. Try any of our Foolish newsletters today, free for 30 days.

Fool contributor Rich Duprey does not have a financial position in any of the stocks mentioned in this article. You can see his holdings here. The Motley Fool has a disclosure policy.


Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On April 20, 2009, at 4:00 PM, PauvrePapillon wrote:

    If you’re fishing for legitimate contender for 10-baggers, why not take a look at Accuray (ARAY)?

    When the market (correctly) understood that CyberKnife was a truly unique and revolutionary technology, investors bid Accuray’s post-IPO shares up to an intraday high of $31.09 (9 February 2007). As Varian and others made repeated claims, in numerous press releases, interviews and conference calls, that their gantry-mounted machines could do the same thing as the robotically controlled CyberKnife, Accuray’s market cap shrank even though its economic fundamentals actually improved.

    On 6 December 2008, Accuray, finally, fired back with the release of two animated videos that effectively demonstrate what CyberKnife is and why it is fundamentally different from gantry-mounted radiation sprayers. You can - and should - see them for yourself at http://www.accuray.com.

    Since then, Accuray shares have gone up 46 percent (as of close of market Friday 17April 2009) while Intuitive Surgical has shed five percent and Varian has dropped 11 percent against the backdrop of a NASDAQ index that is up 11 percent and a DOW that is down six percent.

    Accuray now boasts a Five-Star CAPS rating with 141 out of 145 All Star Players rating ARAY to outperform and 476 out of 494 players overall in agreement.

    http://caps.fool.com/Ticker/ARAY.aspx

    With Accuray you have a serious candidate for a multi-bagger in the making whose underlying technology is still in the early stages of its adoption curve. Peter Lynch would be all over it.

  • Report this Comment On April 23, 2009, at 12:52 AM, chopchop0 wrote:

    ARAY makes one product. A Varian Trilogy machine can do everything a cyberknife does, and more

  • Report this Comment On April 23, 2009, at 12:53 AM, chopchop0 wrote:

    ARAY belongs with TOMO, under $10 a share LOL

  • Report this Comment On April 24, 2009, at 8:59 AM, jakes10 wrote:

    chopchop0

    From you statement you do not understand Radiation Therapy. There is one major difference between the Varian products and the Cyberknife. With the Varian systems they don't care were they deliver the beam as far as that system is concern when they hit the Bean on button the patient could be in the bath room and the system would still make radiation. Cyberknife tracks the tumor in real time not just at the beginning of treatment and will not let therapist turn the bean on in less the tumor is >1mm from where the beam is suppose to go.

  • Report this Comment On April 24, 2009, at 5:05 PM, PauvrePapillon wrote:

    UPDATE:

    Since 6 December 2008 (the release date of Accuray’s technology differentiation videos) to close of market Friday 24 April:

    ARAY is up 46 percent

    NASDAQ is up 12 percent

    ISRG is up 9 percent

    DOW is down 6 percent

    TOMO is down 7 percent

    VAR is down 14 percent

    All this in spite of Varian’s continued misinformation campaign which lifts, in many cases word-for-word, the language used to describe Accuray’s robotically controlled, multi-planer CyberKnife and then applies same to describe the capabilities of their gantry-mounted, co-planer linacs.

    But Varian’s act is growing old… and less effective.

    NOTE: Today Varian issued a press release entitled: “Varian Medical Systems to Exhibit Full Spectrum of Prostate Cancer Treatment Technologies at the American Urological Association Meeting in Chicago.”

    IMMEDIATE RESULT: VAR closed up 2.94 percent.

    BUT: The NASDAQ was up 2.55 percent and ARAY was up a whopping 6.58 percent.

    CONCLUSION A: The more Varian (or anybody else) talks about prostate cancer therapies, the more people reach the (correct) conclusion that CyberKnife is the best treatment option for capsule confined prostate cancer.

    CONCLUSION B: The more investors look at Novalis (or any gantry-based system) versus CyberKnife, the more convinced and confident they become that Accuray really has the goods.

    PREDICTION A: Even though Accuray has had a big run up (46 percent) from 6 December 2008, the instant management started to seriously push back against Varian, and an even larger run up (62 percent) since their 21 November 2008 low of $3.70, look for Accuray to get another boost coming out of the AUA meeting (25 through 30 April) and the Robotic RadioSurgery Course (1 and 2 May).

    PREDICTION B: Accuray’s third quarter fiscal 2009 results, to be released 5 May, will be good enough to show CyberKnife bucking the headwinds against capital spending.

Add your comment.

Compare Brokers

Fool Disclosure

DocumentId: 878818, ~/Articles/ArticleHandler.aspx, 5/25/2012 7:54:31 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 12,454.83 -74.92 -0.60%
S&P 500 1,317.82 -2.86 -0.22%
NASD 2,837.53 -1.85 -0.07%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/25/2012 1:48 PM
SDTHQ.PK $0.05 Down +0.00 +0.00%
ShengdaTech, Inc. CAPS Rating: *****
STO $23.24 Up +0.22 +0.96%
Statoil (ADR) CAPS Rating: ****
VAR $61.36 Up +0.21 +0.34%
Varian Medical Sys… CAPS Rating: ****
NCTY $4.50 Up +0.17 +3.93%
The9 Limited (ADR) CAPS Rating: **
ADBE $31.60 Up +0.06 +0.19%
Adobe Systems CAPS Rating: ***
ASH $64.40 Down -0.81 -1.24%
Ashland, Inc. CAPS Rating: ****
GMK $8.80 Up +0.06 +0.69%
Gruma S.A.B. de C.… CAPS Rating: *****

Advertisement